Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study. Neal, J. W., Lim, F., Felip, E., Gentzler, R. D., Patel, S. B., Baranda, J., Fang, B., Squillante, C., Simonelli, M., Werneke, S., Curran, D., Ponce Aix, S. AMER SOC CLINICAL ONCOLOGY. 2020
View details for Web of Science ID 000560368303508